Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 87.63 (-0.67%)
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 87.63 (-0.67%)
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

ITCI : 87.63 (-0.67%)
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

ITCI : 87.63 (-0.67%)
Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular: Q3 Earnings Snapshot

ITCI : 87.63 (-0.67%)
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

ITCI : 87.63 (-0.67%)
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

ITCI : 87.63 (-0.67%)
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed...

ITCI : 87.63 (-0.67%)
XENE : 41.75 (-0.52%)
AXSM : 97.37 (-0.47%)
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 87.63 (-0.67%)
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted...

ALZN : 1.4600 (+0.69%)
VNDA : 5.10 (-6.59%)
ITCI : 87.63 (-0.67%)
TEVA : 16.75 (-1.12%)
ABBV : 169.63 (-0.42%)

Barchart Exclusives

Stock Index Futures Plunge as Fed Rate Cut Bets Wane, U.S. Retail Sales Data in Focus
December S&P 500 E-Mini futures (ESZ24) are down -0.58%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.90% this morning after Federal Reserve Chair Jerome Powell indicated the central bank was in no rush to lower interest rates, while investors geared up for a flurry of U.S. economic data, with a particular focus on the retail sales report. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar